Literature DB >> 28536454

Immunotherapy: T cells get a ride.

M Teresa Villanueva1.   

Abstract

Mesh：

Year:  2017        PMID： 28536454     DOI： 10.1038/nrc.2017.39

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  2 in total

1.  Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.

Authors:  Martina Schmittnaegel; Nicolò Rigamonti; Ece Kadioglu; Antonino Cassará; Céline Wyser Rmili; Anna Kiialainen; Yvonne Kienast; Hans-Joachim Mueller; Chia-Huey Ooi; Damya Laoui; Michele De Palma
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

2.  Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Authors:  Elizabeth Allen; Arnaud Jabouille; Lee B Rivera; Inge Lodewijckx; Rindert Missiaen; Veronica Steri; Kevin Feyen; Jaime Tawney; Douglas Hanahan; Iacovos P Michael; Gabriele Bergers
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956
  2 in total
  1 in total

1.  Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy.

Authors:  Jakob Nikolas Kather; Anna Sophie Berghoff; Dyke Ferber; Meggy Suarez-Carmona; Constantino Carlos Reyes-Aldasoro; Nektarios A Valous; Rodrigo Rojas-Moraleda; Dirk Jäger; Niels Halama
Journal:  Oncoimmunology       Date:  2018-03-29       Impact factor: 8.110
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.